ohm: My post was exactly what I represented it to be: an

New Post Public Reply Private Reply Replies (0) Message Board
Jake2212 ohm20 #152457
608
ohm: My post was exactly what I represented it to be: an effort to plausibly consider why CYDY was hiring a new CFO given a timing perspective that would likely have diverted attention from the buzz it had created by headlining Dr Jay's upcoming travel to ESMO in Munich. In other words, I was posing the possibility that these 2 seemingly disparate events may actually be somewhat related and, if so, why.

Aware that my hypothesis on the above topic was at the high end of the speculative ladder (note my shout out to MGK), I did try to subtly infuse it in a light hearted writing style that would befit such obvious guesswork on my part. But the only subtle satire I meant to convey (as an attempt at humor) were the 2 references to yesterday's board debate over who to blame for the Alzheimer’s study start up delay ( a debate that you and misui continued this morning).

As to your sage comment regarding the impossibility of the sale of the non oncology portion of the LL pipeline, you (and cardimine) are obviously correct that such a sale would require a SEC filing within a set number of days after its consummation. And no such filing has occurred. But although transactional closings and government filing tradecraft were never my thing, I strongly suspect that if CYDY and a buyer had wished to delay, for PR reasons, the effective date of the purchase agreement by adding a simple to meet contingency, the boys and girls at Sidley Austin would have been up to the task.

So, at the risk of repeating myself. -- my prior life demonstrated to me that deals don't always get successfully negotiated, even when the opportunity for mutual benefits dictates that they should. A successful outcome usually depends on how rationally each side assesses the dispersion of leverage between the parties. Headlining Dr Jay traveling to Munich gave me a sense of confidence that the much anticipated partnership agreement was at hand. However, inserting the new CFO into the news mix at this particular time suggested to me that his appointment might be connected to Munich in some way. If so, one possible explanation would be that the partnership negotiations had, unfortunately, failed, probably because the BP putative partners had overplayed their hand (leverage), thus making it advisable for Jay to announce the appointment of a permanent and highly qualified CFO who could help CYDY chart its own path over the next couple years with the help of vitally necessary cash from EMA granted Conditional Marketing Authorization revenues and the sale of the LL non oncology pipeline. As I thought I made quite clear, this is simply a hypothesis, premised entirely on how CYDY might respond if partnership negotiations had failed.

Now, you may find the above incredulous or even laughable, but it wasn't intended as satire, subtle or otherwise. All of it rests, not only on unverifiable speculation, but on the premise that notwithstanding the headlining of Munich by CYDY, it's possible that a successful partnership negotiation has not transpired over the last several months because reasonable terms were never offered. That premise is hopefully and likely invalid because any BP should realize by now the potential value of LL, and, accordingly, have offered reasonable and fair partnership terms to CYDY. In that case, Jay will be making a partnership announcement in Munich, and we can all assume that CYDY felt that Mr Hoffman will be just as valuable in a partnership setting as in a stand alone CYDY world.

As always, all he best.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

CVRx Lawsuit Puts a Hard Date on Investor Decisions

Updated Category News Views 0

One ugly filing after the bell can vaporize years of shareholder confidence, and CVRx just supplied the painful exhibit. On August 7, 2026, shares of CVRx fell $3.55, or 59.76%, to close at $2.39 after the company disclosed a U.S. Department of Justice civil investigative demand in its August 6 Form 10-Q. That is not a routine bad quarter. It is the sort of disclosure...

Continue Reading
MTI Adds Aviation Veterans as Acorn Builds MRO Plan

Updated Category News Views 95

Two old hands entering a boardroom can matter more than another glossy growth slogan, especially in aircraft maintenance, where a delayed part can ground an airplane and turn a customer relationship sour in a hurry. MTI Aviation has added Tony DiSimone Sr. and Aviv Tzur to its board, a move announced November 20, 2026, after Acorn Capital Management took a majority...

Continue Reading
Africa Tech Festival Puts Trust Ahead of AI Hype Cycle

Updated Category News Views 11

Fifteen thousand people can fill a convention centre, but they cannot magically deliver a package, fund a small business, or repair harm from a bad automated decision. That rather useful dose of reality ran through the final day of Africa Tech Festival 2026 in Cape Town. The 29th edition drew more than 15,000 delegates across three days, and the strongest message was not...

Continue Reading
Home Nursing Plans Need Clarity Before the Next Crisis

Updated Category News Views 61

A medication change scribbled on a loose sheet can become a very long night. That is the unglamorous truth behind the discussion from Michael and Marsha Reda of Aurora Home Care in Williamsville, New York: long-term home nursing care depends on a plan people can actually follow when the household is tired, worried, and juggling too much. Their perspective, featured by...

Continue Reading
Hope Charities Makes Care Funding Easier to Track Online

Updated Category News Views 72

A treatment bill can wreck a household long before a diagnosis does. That is the uncomfortable reality behind Hope Charities' new Access to Care website, a centralized resource meant to show people in the bleeding disorders community when diagnosis-specific charitable assistance funds are available. This is not flashy technology, nor should it be treated like some grand...

Continue Reading
GreenTree Faces Softer Rooms, Debt and NYSE Deadline

Updated Category News Views 18

A hotel operator can post positive earnings and still leave shareholders with a nasty headache, and GreenTree's third quarter is that kind of report. NYSE:GHG produced RMB243.0 million in revenue, down 22.2% from a year earlier, while net income slipped to RMB49.3 million from RMB59.0 million. This was not a one-line stumble. Room pricing, occupancy, franchise economics...

Continue Reading
New York Gala Puts $3 Million Behind EB Research Work

Updated Category News Views 0

Three million dollars changes the temperature in a research room, even if it does not magically solve the hard part. EB Research Partnership said its New York gala raised more than $3 million, with Eddie Vedder, Hozier, Tom Holland and Colin Farrell among the names helping draw attention. For a nonprofit operating around research, that is not a fluffy society-page...

Continue Reading
BBW Lawsuit Puts Guidance and Walmart Claims Under Lens

Updated Category News Views 65

A three-month slice of 2026 has landed Build-A-Bear in the sort of mess investors hate most: a securities complaint centered on whether management's upbeat messaging had already outrun the facts. The lawsuit targets purchases of BBW shares from May 28, 2026 through August 26, 2026, alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and...

Continue Reading
SDG&E's 21-Year Reliability Run Has Real Investor Weight

Updated Category News Views 66

Seventy minutes without power in a year is the sort of number most people ignore until their refrigerator quits humming. For San Diego Gas & Electric customers, though, it is a meaningful operating result: roughly 70 minutes annually from unplanned outages, on average, over the past decade, alongside fewer than one sustained outage per customer each year. SDG&E has also...

Continue Reading
Midea’s SC26 Cooling Pitch Targets AI Build Delays

Updated Category News Views 49

Heat is the uninvited partner in every AI build, and Midea is making a sensible argument that nobody gets paid for racks sitting idle while piping crews wrestle with a complicated cooling plant. At SC26 in Chicago, held November 17 through 19, the company made its North American debut for a modular prefabricated AI data-center cooling setup built around a magnetic coolant...

Continue Reading

Top 5 Most Recently Viewed Articles

Context Labs Launches Innovative Open-Source Emissions Project

Updated Category News Views 204

Context Labs Introduces a Revolutionary Open Decarbonization Project Context Labs is set to make a significant impact in the world of emissions measurement with the launch of its Open Decarbonization Project (ODP). This initiative, in collaboration with key industry players, aims to foster transparency and reliability in carbon and methane emissions reporting using...

Continue Reading
BioAge Labs Exciting Participation in Key Investor Conferences

Updated Category News Views 124

BioAge Labs' Upcoming Investor Conferences BioAge Labs, Inc. (NASDAQ: BIOA), a dynamic player in the biotechnology sector, is ready to take significant strides in the world of investment discussions. This clinical-stage firm specializes in developing therapeutic products targeting metabolic diseases, particularly by exploring the biology of human aging. Engagements at...

Continue Reading
Tiba Biotech’s Revolutionary Vaccine Against Foot-and-Mouth Disease

Updated Category News Views 322

Introduction to Tiba Biotech's Innovative Vaccine Tiba Biotech is at the forefront of changing the landscape of animal health with its novel vaccine specifically designed to combat Foot and Mouth Disease (FMD). This innovative solution has emerged from an extensive challenge study evaluating its effectiveness in cattle, demonstrating that all vaccinated subjects...

Continue Reading
Santhera Pharmaceuticals Secures NICE Clearance for AGAMREE

Updated Category News Views 144

Santhera's Exciting New Journey with AGAMREE® Santhera Pharmaceuticals is making significant strides in the pharmaceutical industry with its innovative medication AGAMREE® (vamorolone), aimed at providing new hope for those affected by Duchenne muscular dystrophy (DMD). With the recent positive guidance from the National Institute for Health and Care Excellence (NICE),...

Continue Reading
Truelink Capital Invests in Horwitz MEP Expansion

Updated Category News Views 57

Truelink Forges New Path with Horwitz Partnership Private equity news always has a way of stirring the pot, and Truelink Capital's latest move is no exception. They announced a significant investment in Horwitz, a Minneapolis-based firm that's been dealing with mechanical, electrical, and plumbing (MEP) services for what seems like a century. Now, they’re digging in...

Continue Reading